source
- Neurocrine’s rare-disease drug approved but later linked to deaths and serious side effectsNeurocrine Biosciences received regulatory approval for a rare‑disease therapy after a small clinical trial showed modest efficacy and side effects that were considered manageable. The decision was…
- California distributes over 120,000 low-cost insulin glargine packs as Novo Nordisk CEO warns investors on obesity drug differentiationCalifornia's state health program has been distributing a low-cost insulin glargine product, more than 120,000 five-pen packs since its launch seven months ago. Each pack is priced at $55, which i…